Table 3 Total Ovaleap® Dose and Duration of Stimulation and Number of Oocytes Retrieved
Previous Treatment in Main Study | |||
|---|---|---|---|
Total Group | Ovaleap® | Gonal-f® | |
Cycle 2 | N = 147 | N = 80 | N = 67 |
Total Ovaleap® dose, IU | |||
Mean (SD) | 1998 (771) | 1925 (706) | 2086 (840) |
Median (range) | 1875 (450–4313) | 1763 (1013–3750) | 2025 (450–4313) |
Duration of Ovaleap® stimulation, days | |||
Mean (SD) | 9.9 (1.8) | 9.7 (1.8) | 10.0 (1.9) |
Median (range) | 10.0 (4.0–14.0) | 10.0 (5.0–14.0) | 10.0 (4.0–14.0) |
Number of oocytes retrieveda | |||
Mean (SD) | 12.1 (5.9) | 12.0 (5.8) | 12.1 (6.0) |
Median (range) | 11.0 (2.0–36.0) | 11.0 (3.0–29.0) | 11.0 (2.0–36.0) |
Cycle 3 | N = 61 | N = 34 | N = 27 |
Total Ovaleap® dose, IU | |||
Mean (SD) | 2113 (939) | 1883 (687) | 2402 (1132) |
Median (range) | 1875 (750–5400) | 1800 (750–3450) | 2100 (788–5400) |
Duration of Ovaleap® stimulation, days | |||
Mean (SD) | 9.9 (1.7) | 9.6 (1.7) | 10.3 (1.7) |
Median (range) | 10.0 (5.0–14.0) | 9.0 (5.0–13.0) | 10.0 (7.0–14.0) |
Number of oocytes retrievedb | |||
Mean (SD) | 13.5 (6.5) | 12.3 (6.2) | 15.0 (6.5) |
Median (range) | 12.0 (3.0–33.0) | 11.0 (3.0–30.0) | 12.0 (6.0–33.0) |